ANAB Stock Analysis: Buy, Sell, or Hold?
ANAB - AnaptysBio, Inc. Common Stock
$63.42
-2.01 (-3.07%)
▼
5d:
+6.27%
30d:
+23.72%
90d:
+11.79%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
30d
Get Alerted When ANAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ANAB shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: ANAB shows positive signals but monitor for confirmation. Market pricing in 2.6% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$82.16
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$51.02
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANAB is currently trading at $63.42, which is considered extended relative to its 30-day fair value range of $52.35 to $62.11. The stock's valuation (Forward PE: 12.1) is in line with its historical norms (11.2). At these levels, the market is pricing in 2.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ANAB is showing sideways momentum. Immediate support is located at $55.16, while resistance sits at $69.27. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: ANAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.09 (+37.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANAB is showing sideways momentum. Immediate support is located at $55.16, while resistance sits at $69.27. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: ANAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $87.09 (+37.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$52.35 -
$62.11
Company Quality Score
57/100
(HOLD)
Options IV Signal
28th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 28th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 37.3% below Wall St target ($87.09)
- NEUTRAL: Market pricing in 2.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$52.35 -
$62.11
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$7.63
(12.0%)
Support & Resistance Levels
Support Level
$55.16
Resistance Level
$69.27
Current Trend
Sideways
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.11
Wall Street Target
$87.09
(+37.3%)
Revenue Growth (YoY)
-8.0%
Profit Margin
-11.5%
Valuation Premium vs History
+2.6% premium
PE vs Historical
12.1 vs 11.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.6%
(market-implied from PE analysis)
1-Year Target
$65.07
(+3%)
2-Year Target
$66.76
(+5%)
3-Year Target
$68.50
(+8%)
3-Yr Target (if PE normalizes)
(PE: 12→11)
PE COMPRESSION
$63.33
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: July 05, 2026 2:35 PM ET
Data refreshes hourly during market hours. Next update: 3:35 PM
Data refreshes hourly during market hours. Next update: 3:35 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
John P Schmid
SELL
20645 shares
2026-03-30
Daniel Faga
SELL
17679 shares
2026-03-27
Eric J Loumeau
SELL
10000 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 67 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |